Background: There has been increasing interest in elucidating the relationship between adenoid hypertrophy (AH) and allergic rhinitis (AR). However, the impact of aeroallergen sensitization patterns on children concurrently experiencing AH and AR remains unclear. Methods: Patients aged 2-8 years (January 2019 to December 2022) with nasal symptoms were assessed for allergies, adenoid size and respiratory viral infection history. The levels of serum total immunoglobulin E (IgE) and specific IgE and flexible nasal endoscopy were performed. We analyzed the relationship between AH and sensitization patterns and lymphocyte subpopulations in adenoid samples using flow cytometry. Results: 5281 children were enrolled in our cohort. 56.5% of children was diagnosed with AR and 48.6% with AH. AR was more prevalent in AH children compared to nAR. Compared to non-sensitized, those with AR polysensitized to molds had a higher prevalence of AH (adjusted OR 1.61, 95%CI 1.32-1.96) and a greater occurrence of two or more respiratory viral infections, particularly in cases with adenoidectomy. In AH-AR children, adenoid tissues showed reduced frequencies and corrected absolute counts of regulatory T cells (Tregs), activated Tregs, class-switched memory B cells (CSMB), natural killer (NK) T cells and NK subpopulations compared to AH-nAR children. Polysensitization in AH-AR children correlated with lower CSMB frequencies. Conclusion: Polysensitivity to molds significantly increased the risk of AH in children with AR. Adenoids of AR children demonstrated less number of B cells, NK cells and Treg cells with an effector/memory phenotype, which was closely linked to sensitization models and respiratory viral infection, particularly concerning CSMB.

Background: Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy (19CAR-T) has achieved impressive clinical achievements in both adult and pediatric relapsed/refractory (r/r) B-lineage acute lymphoblastic leukemia (B-ALL). However, the application and effect of CAR-T therapy in B-ALL patients with extramedullary relapse are rarely issued even disqualified in some clinical trials. Here, we examined the efficacy of 19CAR-T in patients with both bone marrow and extramedullary involvement. Methods: CAR-T cells were generated by a lentiviral vector transfection into primary human T lymphocytes to express anti-CD19 and anti-CD22 single chain antibody fragments (scFvs) with the cytoplasmic domains of 4-1BB and CD3ζ. Patients diagnosed as r/r B-ALL with extramedullary origination were infused with anti-CD19 CAR-T cells. The clinical responses were evaluated by bone marrow aspiration, imaging, and flow cytometry examination. Results: A total of 8 patients received 19CAR-T infusion and all of them acquired complete remission (CR), in which only 1 patient was bridged to hematopoietic stem cell transplantation (HSCT). Even though there were 3 patients relapsed after infusion, they received 19/22CAR-T infusion sequentially and acquired the second remission. To date, 5 patients are continuous CR, and all patients are still alive. The mean follow-up time was 21.9 months while the 24-month estimated event-free survival (EFS) is 51.4%. Conclusions: Anti-CD19 CAR-T therapy can lead to clinical remission for extramedullary relapsed pediatric B-ALL patients. However, the problem of CD19+ relapses after CAR-T remained to be solved. For patients relapsing after CAR-T, the second CAR-T therapy suggests creating another opportunity of remission for subsequent HSCT.